Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Hey narmac
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by narmacon Jan 25, 2023 4:51am
97 Views
Post# 35244367

RE:Hey narmac

RE:Hey narmacAgreed Beenthere,,,,,is all lost?,,not by a long shot imo,,,,,those who are not wishing to have input into their investment have that right to do so. Why blame anyone else for their lack of response. If you dont want to discuss possibilities and make calls and get involved you probably dont use proxyvote and dont intend to,,,or have never provided input before.

I would like to see DrDR step down and release these advisory boards. The BoDs might need to be replaced as they cant help this company anymore than what they have shown or were voted down in other paths put forward. I don not believe we had or have only one option going forward!!

We need a CEO with a vision, connections and negotiating skills. Priority #1 is to safe guard our IP and minimize the number of payouts. Our payroll must be scaled according to our business model. We are not in the lab and we should be minimum in number going forward. Our partners might also release important data that would reflect in an increase in share price over the coming months! We are not being told of any postiive developments expected from partrners!

I do have optimism for our future. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities